Antimessenger oligonucleotide against urokinase receptor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 16, 1999
Grant Date -
N/A
app pub date -
Feb 27, 1997
filing date -
Jul 22, 1994
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Antisense oligonucleotides optionally stabilized with phosphorotioate residues or analogues, or modified in the whole sugar-phosphate backbone--complementary to the human urokinase receptor messenger RNA--are able to prevent invasiveness of neoplastic cells by inhibiting the overexpression of the receptor itself, directly responsible of the invasive phenotype. Said oligomers are useful as medicaments for the treatment of primary and secondary neoplasias as well as of other pathologies wherein the urokinase receptor gene overexpression is a pathogenic event.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully